Platelet Sub-study of the Neomindset Trial

Inclusion criteria: * Age \>=18 years; * Clinical presentation compatible with acute coronary syndrome with onset \< 24 hours before admission; * Successful percutaneous coronary intervention(s) of all target lesions (culprit and non-culprit) with new-generation drug-eluting stents; * Length of stay in hospital at randomization \< 96 hours; * Subjects will be informed about the nature of the study and must agree to comply and give an informed consent in writing using a form approved in advance by the local Ethics Committee. Exclusion Criteria: * Acute coronary syndrome on index admission treated in a conservative way or by unsuccessful percutaneous intervention or surgically; * Presence of residual lesions which are likely to require future treatment in the next 12 months; * Fibrinolytic therapy \< 24 hour before randomization; * Need of oral anticoagulation with warfarin or new anticoagulants; * Chronic bleeding diathesis; * Active or recent major bleeding (in-hospital); * Prior intracranial hemorrhage; * Ischemic cerebrovascular accident \< 30 days; * Presence of brain arteriovenous malformation; * Index event of non-atherothrombotic etiology (i.e., stent thrombosis, coronary embolism, spontaneous coronary artery dissection, myocardial ischemia due to supply/demand imbalance); * Potential or scheduled cardiac or non-cardiac surgery in the next 12 months; * Platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3; * Total white blood count \< 3,000 cells/mm3; * Suspected or documented active liver disease (including laboratory evidence of hepatitis B or C); * Receiver of heart transplant; * Known allergies or intolerance of acetylsalicylic acid, clopidogrel, ticlopidine, ticagrelor, prasugrel, heparin or antiproliferative agents from the limus-family of drugs; * Subject with life expectation lower than 1 year; * Any significant medical condition that, in the investigator's opinion, could interfere with the ideal participation of the subject in the study; * Participation in other study in the past 12 months, unless a direct benefit to the subject can be expected. * Impossibility of being treated with dual antiplatelet therapy for 12 months, based on investigator judgement.